Work

Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG

Year: 2012

Type: article

Source: Cancer Immunology Immunotherapy

DOI: 10.1007/s00262-012-1372-8

Authors: Kory L. Alderson, Mitchell Luangrath, Megan M. Elsenheimer, Stephen D. Gillies, Fariba Navid, Alexander L. Rakhmilevich, Paul M. Sondel

Institutions: University of Wisconsin–Madison, University of Vermont, St. Jude Children's Research Hospital, University of Wisconsin Carbone Cancer Center

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Defense, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences

Awards: G2649204724, G3013949418, G42679306, G5461654644, Clinical Development of HU14.18-IL2 Targeted Therapy, G761604651, G7633113169, G812711444, G8136105410, G8359829046

OpenAlex ID: W1973699352

FWCI: 0.862

Cites: 49

Cited by: 23

Related to: 10